...with the full dataset coming by May. MK-7110, which Merck gained through its $425 million acquisition of OncoImmune Inc. in...

...treat patients with severe and critical COVID-19. Merck gained the program through its $425 million takeout of OncoImmune Inc. last...

...By Virginia Li, Associate Editor OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid...
...which includes undisclosed milestones and royalties, Merck & Co. Inc. (NYSE:MRK) will gain lead candidate CD24Fc. OncoImmune Inc....
...September, after raising a $56 million series B round to fund its late stage studies, OncoImmune...

...By BC Staff OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B...
...Wisconsin. Completion is expected by mid-2022. TARGETSCB1 (CNR1) – Cannabinoid receptor 1CD47FAK – Focal adhesion kinase BC Staff OncoImmune Inc. Inversago...

...is now $56.45 (see "Updated Data Bring NextCure Back to Earth" ). Other companies, including OncoImmune Inc....
...opposite direction, co-opting SIGLEC ligands to develop immune-tolerizing therapies for diseases driven by excess inflammation. OncoImmune's...
...human tissue samples. The SIGLEC10/CD24 axis is also gaining traction as a therapeutic target, beyond OncoImmune's...

...a recombinant fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain. OncoImmune...
...for autoimmune disorders, cancer or GvHD. The company did not respond to inquiries. Last year, OncoImmune...
...to ONC-392 , a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152) inhibitor. OncoImmune...

...million in a series A round led by 3E Bioventures Capital. OncoImmune Inc. , Rockville, Md. Alex Himes OncoImmune Inc....

...against cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ), and additional anti-CTLA4 antibodies. OncoImmune...
...said it plans to evaluate ONC-392 in immuno-oncology. The companies declined to provide additional details. OncoImmune Inc....

...to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ) inhibitor. OncoImmune...

...of the disease. The authors suggested CD24 could be a useful target for treating MS. OncoImmune...